Pharmaids Pharmaceuticals Intrinsic Value
Pharmaids Pharmaceuticals (PHARMAID) median intrinsic value is ₹27.43 from 2 valuation models (range ₹16–₹27), vs current price ₹34.00 — -19.3% downside (Trading Above Median Value), margin of safety -24.0%. Read PHARMAID dividend track record for the complete payout history and dividend yield track record.
PHARMAID Valuation Methods Summary — DCF, Graham Number & P/E
Pharmaids Pharmaceuticals intrinsic value across 2 models vs current price ₹34.00 — upside/downside and value range per method. For current market price and key ratios, visit Pharmaids Pharmaceuticals share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹27.43 | ₹24.69 - ₹30.17 | -19.3% | Book Value/Share: ₹13.71, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹16.00 | ₹14.40 - ₹17.60 | -52.9% | Revenue/Share: ₹8.00, P/S: 2.0x |
PHARMAID Intrinsic Value vs Market Price — All Valuation Models
Pharmaids Pharmaceuticals fair value range ₹16–₹27 vs current market price ₹34.00 across 2 valuation models. Analyse Pharmaids Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
PHARMAID Intrinsic Value Analysis — Undervalued or Overvalued?
Pharmaids Pharmaceuticals median intrinsic value ₹27.43, current price ₹34.00 — Trading Above Median Value by 19.3%, margin of safety -24.0%.
What is the intrinsic value of PHARMAID?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Pharmaids Pharmaceuticals (PHARMAID) is ₹27.43 (median value). With the current market price of ₹34.00, this represents a -19.3% variance from our estimated fair value.
The valuation range spans from ₹16.00 to ₹27.43, indicating ₹16.00 - ₹27.43.
Is PHARMAID undervalued or overvalued?
Based on our multi-method analysis, Pharmaids Pharmaceuticals (PHARMAID) appears to be trading above median value by approximately 19.3%.
PHARMAID Financial Health — Key Ratios vs Industry Benchmarks
Pharmaids Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.69 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -8.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.32x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
PHARMAID Cash Flow Quality — Operating & Free Cash Flow
Pharmaids Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-14 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-11 Cr | ₹-49 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-4 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |